09.10.2015 • NewsDede WillamsLanxessMatthias Zachert

Lanxess CEO Says China Concerns Overblown

Investor concerns about weakening business in China are overblown, Lanxess CEO Matthias Zachert said in an interview with the news agency Reuters. His assertions echoed recent remarks by Patrick Thomas, CEO of Covestro – the former Bayer MaterialScience – who described the Chinese slowdown as a “wobble.”

While the Lanxess chief acknowledged that his group’s business with the People’s Republic has been weaker in the second half of 2015, as expected, he said the German specialty chemicals producer’s view of the market, which accounts for about 13% of its sales, has not deteriorated since August.

Compensating for the Chinese softness, Zachert said markets in Germany and southern Europe as well as demand from US customers in the automotive and construction industries have surpassed expectations. On the downside, the recession in Brazil’s market, where Lanxess has rubber production facilities, has made for sluggish business.

All in all, Zachert said Lanxess expects to be able to report a 10% rise in EBITDA against the 2014 period when revealing Q3 2015 results on Nov. 5. Management’s guidance for full year EBITDA, in the range of €840-880 million, is anticipated to remain "roughly intact.”

The German group's earnings prospects have brightened over the year, Zachert told Reuters. He attributed the improvement to lower raw material costs, a strong US dollar and the acceleration of internal cost-cutting measures aimed at softening the blow of global overcapacity in the synthetic rubber industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.